Almost one third of Americans are currently considered obese.1 As the number of patients with cancer who are overweight is increasing, the conventions of chemotherapy dosing are constantly being questioned. Because of the concern for overdosing obese patients, clinicians are routinely tasked with questions such as—Should we use actual body weight, ideal body weight, or something in between? Should we cap doses? Overdosing patients is a concern for all clinicians, but underdosing may be just as problematic.
The development of ipilimumab (Yervoy) and its approval by the US Food and Drug Administration (FDA) in March 2011 have opened a new era in the treatment and management of patients with metastatic melanoma. The continued innovation in cancer drug development has been focused on a different mechanism of action that engages the patient’s own immune system in attacking malignancy in contrast to the more traditional myelosuppressive drugs that have been used in the past half century to kill rapidly dividing cancer cells.
Results 1 - 8 of 8